According to the recent study published in the Journal of American Medical Association, a new topical treatment for atopic dermatitis (AD) has been shown as a safe, effective, and ...
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of ...
(RTTNews) - Arcutis Biotherapeutics Inc.'s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ...
Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and ...
This would make them descend more slowly. Next, the integument, the feathers and skin, could have expanded to make larger surfaces which could con trol descent more effectively. We see an incipient ...
在其他近期新闻中，Arcutis Biotherapeutics报告2024年第二季度业绩强劲，净收入达到30.9百万美元，较第一季度净产品收入增长43%。这一增长主要由其皮肤病产品（包括Zoryve乳膏和泡沫）的处方量显著增长推动。Mizuho Securities和TD ...
Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopic dermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback